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Abstract
Small- and intermediate-conductance Ca2+-activated potassium channels, activated by Ca2+-bound 
calmodulin, play an important role in regulating membrane excitability. These channels are also 
linked to clinical abnormalities. A tremendous amount of effort has been devoted to developing 
small molecule compounds targeting these channels. However, these compounds often suffer from 
low potency and lack of selectivity, hindering their potentials for clinical use. A key contributing 
factor is the lack of knowledge of the binding site(s) for these compounds. Here we demonstrate 
by X-ray crystallography that the binding pocket for the compounds of the 1-EBIO class is located 
at the calmodulin-channel interface. We show that, based on structure data and molecular docking, 
mutations of the channel can effectively change the potency of these compounds. Our results 
provide insight into the molecular nature of the binding pocket and its contribution to the potency 
and selectivity of the compounds of the 1-EBIO class.
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Ca2+-activated potassium channels, such as small- and intermediate-conductance K+ 
channels (SK and IK), are widely expressed in excitable tissues, including the central 
nervous system and the cardiovascular system1–5. They play pivotal roles in regulating 
membrane excitability by Ca2+. Unlike voltage-gated K+ channels, activation of SK/IK 
channels is voltage-independent and is achieved exclusively by Ca2+6. Calmodulin (CaM), 
constitutively tethered to SK/IK channels, serves as the high-affinity Ca2+ sensor. Four 
canonical EF-hands, two located at the CaM N terminus (N-lobe) and the other two at the C 
terminus (C-lobe), are the high affinity Ca2+ binding domains7. Binding of Ca2+ to CaM 
results in changes in the CaM conformation and subsequent opening of the channel8–10. 
Both SK and IK channels belong to the same gene family, with four genes identified, 
KCNN1 for SK1, KCNN2 for SK2, KCNN3 for SK3 and KCNN4 for IK channels3,5. We 
have identified an SK2 channel splice variant, SK2-b, which is less sensitive to Ca2+ for its 
activation10. Activation of SK channels dampens firing of action potentials, and therefore 
contributes to regulation, by Ca2+, of neuronal excitability, dendritic integration, synaptic 
transmission and plasticity in the central nervous system1,3,5,11. Equally important are the 
roles of SK/IK channels in the cardiovascular system12–15. Vascular endothelial cells 
express both IK and SK3 channels, which contribute to the endothelium-derived 
hyperpolarizing factor (EDHF)-mediated vasodilation16–19. Increased SK/IK channel 
activities promote arteriolar vasodilation by enhancing agonist-evoked synthesis of nitric 
oxide in endothelial cells20.
The functional importance of SK/IK channels is further demonstrated by their potential 
involvement in clinical abnormalities14,21–23. CGA repeats of SK3 channels have been 
linked to schizophrenia and the bipolar disorder24–25. Single-nucleotide polymorphisms 
(SNPs) in the SK/IK genes have been implicated in cardiovascular abnormalities21. In the 
heart, genome-wide association studies reveal a correlation of SNPs of SK3 channels and 
atrial fibrillation26. Compromised SK channel activities may be a contributing factor of 
hypertension14. IK channels are implicated in atherogenesis in mice and human27. Recent 
studies have also suggested the potential link of SK channels and development of cancer, as 
abnormal expression of SK2 and SK3 channels might contribute to enhanced cell 
proliferation and cell migration23,28. Given the roles of SK/IK channels in physiological and 
pathophysiological conditions, a tremendous amount of effort has been devoted to 
developing small molecules targeting SK/IK channels11,28–32.
1-ethyl-2-benzimidazolinone (1-EBIO) is such a small molecule prototype, which 
potentiates the SK/IK channel activities and effectively decreases the neuronal excitability, 
thus potentially neuroprotective33. Indeed, studies on animal models have shown that 1-
EBIO can reduce seizure incidence in seizure models34 and significantly improve survival of 
hippocampal neurons after cerebral ischemia22. SKA-31, a different channel modulator, 
enhances the EDHF-mediated responses and lowers the blood pressure35. In general, for 
compounds of the 1-EBIO class, problems include the low potency and lack of selectivity, 
which hamper their potential for evaluation in animal models and in clinical trials2,11. For 
instance, the EC50 of 1-EBIO is in the sub-millimolar range for its potentiation of SK2 
channels11. NS309, although the most potent one of the 1-EBIO class, potentiates both IK 
and SK channels. CyPPA is relatively more selective, acting on SK2 and SK3 channels, but 
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not SK1 or IK channels36. A key contributing factor is the lack of knowledge of the binding 
site(s) for these compounds in SK/IK channels, although the channel C-terminus is 
implicated for the action of 1-EBIO37. So far, it is not known where or how compounds of 
the 1-EBIO class interact with SK/IK channels.
Here we describe our discovery of the functional binding pocket at the CaM-channel 
interface of the CaM N-lobe for compounds of the 1-EBIO class, through the combined 
approaches of X-ray crystallography, molecular docking, mutagenesis and 
electrophysiology. We also show that phenylurea (PHU) is the most prelimitive structure of 
the SK channel modulators of the 1-EBIO class. Our results provide insight into the 
molecular nature of the binding pocket and its contribution to the potency and selectivity of 
the compounds of the 1-EBIO class. The knowledge will facilitate development of future 
generations of therapeutics targeting SK/IK channels.
RESULTS
Phenylurea is a weak SK channel modulator
We previously reported that CaM, when complexed with the CaM binding domain 
(CaMBD) of a SK2 channel splice variant SK2-b (CaMBD2-b), adopts a drastically 
different conformation at the CaM C-lobe10. Such conformational changes have restored the 
ability of the CaM C-lobe to bind Ca2+ ions with reduced affinity, which accounts for the 
reduced sensitivity of activation of SK2-b channels by Ca2+. In solving the structure of the 
CaM-CaMBD2-b complex (PDB accession code 3SJQ), it was discovered that phenylurea, 
an additive in the crystallization solution, is found at the CaM-CaMBD interface of the CaM 
N-lobe, but not the CaM C-lobe (Fig. 1a). The presence of PHU does not interfere with 
Ca2+-dependent formation of the 2×2 CaM-CaMBD2-b complex10. The interaction between 
PHU and the CaM complex is further confirmed by the protein crystal structure, at the 
resolution of 1.7 Å, obtained by soaking in the PHU solution of the CaM-CaMBD2-a 
complex crystals which had been grown in the absence of PHU.
Structural analysis shows extra electron density which corresponds to the structure of PHU 
in the CaM-CaMBD2-a complex (Fig. 1b and Supplementary Figs. S1a and 1b, Table 1). 
Like the CaM-CaMBD2-b complex (Fig. 1a), PHU is located at the interface of CaM-
CaMBD2-a of the CaM N-lobe, forming close contacts with both CaM and CaMBD2-a. 
There are no significant global changes in the structure of the 2×2 configuration of the CaM-
CaMBD2-a complex8,10. The PHU binding pocket includes A477, L480 and V481 of 
CaMBD, F19, I27, L32, M51, I52, V55, I63, F68 and M71 of CaM (within the 5 Å radius of 
PHU, Figs. 1b and 1c, and Supplementary Fig. S1). Compared to the original structure of 
CaM-CaMBD2-a (1G4Y)8, presence of PHU alters the spatial orientation of amino acids, 
including L480, F19, M51, V55 and M71 (Fig. 1b). Within the binding pocket, the urea-
group of PHU can adopt two different conformations (flip-flop, Supplementary Fig. S1c). 
The most intriguing and unexpected discovery comes from the comparison of the chemical 
structure of PHU with the known SK/IK channel modulators, such as 1-EBIO and NS309. 
There is a striking resemblance of the PHU structure to those of 1-EBIO and NS309 (Fig. 
1d).
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To explore whether PHU might act as an SK channel modulator, SK2-a channels were 
expressed in TsA cells and their responses to application of PHU were recorded in the 
presence of 200 nM Ca2+ in the bath solution10. SK2-a channels open upon application of a 
200 nM Ca2+ solution (Fig. 2a). The channel activity is further potentiated with increasing 
PHU concentrations, from 0.2 mM up to 20 mM, with the EC50 of 1.61 ± 0.20 mM and a 
Hill coefficient of 1.81 ± 0.22 (n = 4). The same experiments were repeated using other 
known SK channel modulators, such as 1-EBIO, DCEBIO, CyPPA and NS30911. Compared 
to 1-EBIO (EC50 = 395.5 ± 45.2 μM, n = 5), PHU is much less potent in its potentiation of 
SK2 channels (p < 0.001, T-test, Fig. 2b). PHU is almost 75-fold less potent than DCEBIO 
(EC50 = 21.5 ± 2.7μM, n =8, Fig. 2c) and more than 3600-fold less potent compared to 
NS309 (EC50 = 0.44 ± 0.13 μM, n = 3). CyPPA, which selectively potentiates SK2 and SK3 
channels36, is ~266-fold more potent than PHU (6.04 ± 1.04 μM, n = 6). SK2-b, a SK2 
splice variant10, has the same responses as SK2-a to NS309, 0.50 ± 0.09 μM (n = 6, p = 
0.713, T-test, Fig. 2d). This demonstrates that SK2-b, while less sensitive to Ca2+ for its 
activation10, has the same response to the SK channel modulator as SK2-a.
1-EBIO binds to the same pocket as PHU
The above observation led us to test whether, like PHU, SK channel modulators of the 1-
EBIO class might also bind to the same CaM-CaMBD interface at the CaM N-lobe. Protein 
crystals of CaM-CaMBD2-a, grown without SK channel modulators, were soaked in the 
crystallization solution supplemented with saturating amount of 1-EBIO. The structure of 
the protein complex with 1-EBIO was resolved at the resolution of 1.7 Å. Again, there exists 
extra electron density, at the same location of the CaM N-lobe (e.g. Fig. 1a), but not the 
CaM C-lobe (Fig. 3a and Supplementary Fig. S2a, Table 1). Likewise, no significant global 
changes are observed in the structure of the CaM-CaMBD2-a complex. The 1-EBIO binding 
pocket consists of A477, L480 and V481 of CaMBD2-a and F19, I27, L32, M51, I52, V55, 
I63, F68, M71 and M72 of CaM (within the 5 Å radius of 1-EBIO), virtually identical to the 
PHU binding pocket (Fig. 3b). Compared to the structure without 1-EBIO (PDB accession 
code 1G4Y), several of these residues display different spatial orientations, most noticeably 
A477 and L480 of CaMBD and F19, M51, V55 and M71 of CaM (Fig. 3a). For instance, in 
the absence of 1-EBIO or PHU, M71 of CaM forms close contacts with A477 and L480 of 
CaMBD (Supplementary Fig. S2b). Such interactions are completely disrupted by either 1-
EBIO or PHU, leading to formation of the binding pocket for 1-EBIO or PHU (Fig. 3c and 
Supplementary Figs. S2c and S2d). Depending on whether the ligand is PHU or 1-EBIO, 
these amino acids may adopt different conformations, e.g. L480, F68 and M71, (Fig. 3b). 
Furthermore, the benzene ring of 1-EBIO adopts a different spatial orientation compared to 
that of PHU (Fig. 3d). Unlike PHU, 1-EBIO does not show flip-flop within its binding 
pocket.
Predicted binding pockets for other 1-EBIO compounds
Poor solubility of NS309 and CyPPA in water made it difficult to get protein crystals with 
these compounds. We therefore turned to molecular docking and molecular dynamics (MD) 
simulations to test whether DCEBIO, NS309 and CyPPA might also fit into the same 
binding pocket for PHU and 1-EBIO. Both molecular docking and MD simulations were 
performed using protein coordinates from the PHU-bound CaM-CaMBD structure after 
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removal of PHU. The Generalized-Born with molecular volume (GBMV) implicit solvent 
model was used to calculate the linear interaction energy (LIE(GBMV)) to score individual 
poses obtained from docking and MD modeling38–39. We started by testing whether 
molecular docking and MD simulations would correctly dock both PHU and 1-EBIO in their 
respective native conformations determined from the protein crystals (Figs. 1 and 3). Both 
rigid-receptor and “flexible-receptor” approaches were used to characterize putative binding 
modes for PHU and 1-EBIO. Rigid-receptor docking is able to successfully re-dock PHU 
into the PHU pocket with the difference between the experimental and predicted poses of 
1.30 Å rmsd (root-mean square deviation, calculated over 10 heavy atoms). Likewise, 1-
EBIO is able to dock into the PHU pocket with low energy unstrained ligand geometries and 
favorable LIE(GBMV) scores. The difference of the experimental and predicted poses of 1-
EBIO is 2.44 Å rmsd (calculated over all 12 heavy atoms), which arises primarily from the 
symmetry related conformation of the ethyl group of 1-EBIO (5.50 Å rmsd), while the 10 
atoms of the fused ring system only differ by 1.05 Å rmsd.
Unlike 1-EBIO, the rigid-receptor docking does not work well in docking both di-chloral 
compounds (DCEBIO and NS309) into the PHU pocket. The top-ranked binding geometries 
of these ligands exhibited strained ligand conformations, particularly, the clashes of both 
ligands with F68, M71 and M72 of CaM, consistent with the observation of the crystal 
structures that F68 and M71 change their conformation when the ligand is 1-EBIO instead 
of PHU (Fig. 3b). Receptor ensemble docking (RED) was performed using conformations 
generated from both MD simulations and from low energy rotamers built from the PHU-
bound crystal structure40. Top-ranked ligand pose clusters were identified for each receptor 
conformation using the LIE(GBMV) scores. Comparison of top-ranked clusters across the 
ensemble of receptor conformations demonstrated a reasonable consensus ligand binding 
geometry for DCEBIO and NS309, such that at least three of the top five ranked clusters 
were within 1.0 Å heavy atom rmsd from each other. Compared to NS309 and DCEBIO, 
CyPPA is a much bigger molecule. Nevertheless, rigid-receptor docking works reasonably 
well and is able to dock CyPPA into the PHU binding pocket. Fig. 4 illustrates the predicted 
conformations for DCEBIO (Fig. 4b), NS309 (Fig. 4c) and CyPPA (Fig. 4d) and comparison 
of these conformations to those of PHU and 1-EBIO obtained from crystals (Fig. 4a). We 
also examined whether the NS309 tautomers might have different conformations when 
docked in the PHU pocket. All three tautomers are predicted to have the same conformation 
in the PHU pocket (Supplementary Fig. S3). The top-ranked poses of these compounds are 
further evaluated by a regression-based pair potential (S2 scoring) to predict their binding 
energy. Qualitatively, there is a positive correlation of the predicted binding energy and the 
EC50 for each compound in their potentiation of the SK2 channel activities (Fig. 4e). 
Among the five compounds, NS309 is clearly an exception in that it is over 100-fold more 
potent than the prediction (see discussion).
The CaM-CaMBD interface is the functional binding pocket
Site-directed mutagenesis was carried out to determine whether the CaM-CaMBD interface 
at the CaM N-lobe, identified from our structural data (Figs. 1 and 3) or predicted by 
molecular docking (Fig. 4), represents the functional binding pocket for compounds of the 1-
EBIO class. Previous studies show that 1-EBIO is more potent in potentiating the IK 
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channel activity than that of SK channels11,33. In the CaM-CaMBD2-a complex, the channel 
fragment, E469 – Q487, interacts with the CaM N-lobe in the presence of Ca2+8,10. 
Sequence alignment of IK and SK shows that of these 19 amino acids 11 are different 
between IK and SK2, including A477, L480 and V481, implicated in formation of the 
binding pocket for PHU or 1-EBIO (Figs. 1, 3, 5a and 5b). Mutagenesis studies were 
performed to test whether mutant channels might respond differently to potentiation by 1-
EBIO or other channel modulators. A double mutant, A477V/L480M, was created and its 
responses to 1-EBIO were tested. A second mutant, T479S, was generated to test whether 
amino acids, which are different between IK and SK2 but are not involved in formation of 
the binding pocket for 1-EBIO (Fig. 3b), might have any impact on the effects of 1-EBIO.
Both A477V/L480M and T479S mutants are activated in response to application of 200 nM 
Ca2+. Their responses to application of 1-EBIO, however, differ from each other 
significantly. The EC50 for potentiation of A477V/L480M by 1-EBIO is 40.0 ± 7.0 μM (n = 
4), a 10-fold reduction compared to that of WT SK2-a (p < 0.001, T-test, Figs. 5c and 5d). In 
contrast, the EC50 for potentiation of T479S remains the same as that of WT (EC50 = 316.8 
± 40 μM, n = 4, p = 0.245, T-test, Fig. 5c), consistent with our structure data that T479 is not 
part of the binding pocket (Figs. 1, 3 and 5). While A477V/L480M becomes more sensitive 
to potentiation by 1-EBIO, there is no change in its Ca2+-dependent activation (EC50 = 0.32 
± 0.01 μM, n = 3, Supplementary Fig. S4). The unique role of A477 was further tested by 
additional mutants with the Ala residue replaced by much bulkier amino acid residues, such 
as Ile or Leu. We reasoned that bulkier residues at position 477 might clash with the channel 
modulators and therefore interfere with the interaction between the channel modulators and 
their binding pocket (e.g. Figs. 6a and 6b).
Both A477L and A477I were activated upon application of 200 nM Ca2+ (e.g. Fig. 6c). 
A477L was tested for its response to 1-EBIO in the presence of 200 nM Ca2+. Even at the 
saturating concentration of 1-EBIO, we were not able to obtain the maximal response by 
A477L, indicating that 1-EBIO becomes less potent in potentiation of the A477L mutant 
(data not shown). We next tested the effects of NS309, a more potent modulator, on these 
mutants. A477I becomes less responsive to potentiation by NS309 as compared to WT 
(Figs. 6c and 6d). On average, there is a 5-fold increase in the EC50 for A477I (2.21 ± 0.39 
μM, n = 3), compared to that of WT (0.44 ± 0.13 μM, n = 3, p = 0.013, T-test). In contrast, 
when NS309 was tested on A477V/L480M, the EC50 is significantly reduced (Fig. 6d), at 
0.13 ± 0.009 μM (n = 4, p = 0.039, T-test, compared to WT). Like A477V/L480M, Ca2+ 
dependent activation of A477I remains the same as WT (EC50 = 0.33 ± 0.03 μM, n = 3). 
The results suggest that NS309 binds to the same pocket as 1-EBIO, supporting the 
prediction by molecular docking (Fig. 4). Collectively, mutations, generated based on the 
structure data, can effectively increase or decrease the potency of both 1-EBIO and NS309, 
supporting the notion that the binding site, identified by our structure data, is indeed a 
functional binding pocket for the compounds of the 1-EBIO class.
Targeting the CaM-channel interface alters specificity
Compared to other compounds of the 1-EBIO class, CyPPA, a much bigger molecule (c.f. 
Fig. 1d and Supplementary Fig. S5a), is more selective, which potentiates SK2 and SK3 
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channels with little effect on SK1 or IK channels36. Molecular docking and MD simulations 
predicted that CyPPA could bind to the same binding pocket as 1-EBIO (Figs. 4 and 7a). It 
was further predicted that the A477V/L480M mutation might change the local environment 
of the binding pocket and force CyPPA to adopt a different conformation (Figs. 7b and 
Supplementary Fig. S5). Such predictions were tested by electrophysiology combined with 
mutagenesis. CyPPA is reasonably potent (EC50 = 6.04 ± 1.04 μM, n = 6, Fig. 2c). 
However, the response of A477V/L480M to CyPPA is distinctively different from that of 1-
EBIO (Fig. 5c). A477V/L480M barely increases its current amplitude upon application of 
100 μM CyPPA (Figs. 7c and 7d). Subsequent application of NS309 produces robust 
potentiation (Fig. 7c), indicating that A477V/L480M has virtually lost its response to 
CyPPA. In contrast, V481T yields an EC50 of 5.29 ± 1.01 μM (n = 3) for CyPPA, same as 
the WT (p = 0.666, T-test). The results again support the prediction, by molecular docking, 
that the binding site at the CaM-CaMBD interface, identified by our structure data, is the 
functional binding pocket for compounds of the 1-EBIO class. Furthermore, mutations 
A477V/L480M mimicks the selective effect of CyPPA on IK channels.
DISSCUSSION
This study represents the first to demonstrate the location of the functional binding pocket 
for compounds of the 1-EBIO class. Several lines of evidence support this conclusion. First, 
PHU, a weak SK2 channel modulator, is found in the identical location at the CaM-CaMBD 
interface obtained from two CaMBD splice variants, CaMBD2-b and CaMBD2-a, under two 
different conditions to grow the protein crystals: co-crystallization or soaking of the naïve 
crystals in the PHU solution. Second, 1-EBIO is found to be at the same location as PHU in 
the CaM-CaMBD complex. Third, both PHU and 1-EBIO pockets are found at the CaM N-
lobe, but not at the CaM C-lobe, despite the same hydrophobic nature of the CaM-CaMBD 
interface at the CaM C-lobe, indicating the specificity of the interaction between PHU/1-
EBIO and their binding pockets. Forth, mutations of amino acids, which form the binding 
pocket, can change the potency of 1-EBIO, NS309 and CyPPA. Finally, mutations of amino 
acids not involved in formation of the binding pocket have the same responses to 1-EBIO or 
CyPPA as WT. The results are also consistent with a previous report that the channel C-
terminus is responsible for the action of 1-EBIO37.
With few exceptions, compounds of the 1-EBIO class have low potency, with EC50s up to 
hundreds of micromolars in their potentiation of SK channels (see ref. 11 for a list of EC50s 
by different compounds). The low potency also contributes to the poor therapeutic index for 
these compounds2,34. Thus far, NS309 is the most potent SK/IK channel modulator, with the 
EC50 in the sub-micromolar range (Fig. 2c). Clearly, chemical modification of the 
compound has led to such a dramatic improvement in the potency41. Identification of the 
functional binding pocket allows us to evaluate whether the environment of the binding 
pocket may also play a role in determining the potency of compounds of the 1-EBIO class. 
Indeed, mutations, such as A477V/L480M and A477I, can significantly alter the potency of 
1-EBIO or NS309 (e.g. Figs. 5 and 6). Molecular docking allows us to put DCEBIO, NS309 
and CyPPA in the same binding pocket (Fig. 4), and the results of molecular docking are 
corroborated by effects of mutations on the effectiveness of NS309 and CyPPA (Figs. 6 and 
7). Molecular docking and MD modeling further show, qualitatively, a correlation of 
Zhang et al. Page 7
Nat Commun. Author manuscript; available in PMC 2013 February 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
improved interactions of the compounds with the binding pocket and their potency for PHU, 
1-EBIO, DCEBIO and CyPPA (Fig. 4). NS309, however, is an exception, with its potency 
over 100-fold higher than the prediction (Fig. 4). NS309 is likely to bind to the same binding 
pocket as 1-EBIO, since both A477V/L480M and A477I mutants change the potency of 
NS309 (Fig. 6). Molecular docking puts NS309 in a somewhat different position from that 
of 1-EBIO (Fig. 4c). Three potential scenarios may explain why NS309 is an outlier in Fig. 
4e. First, the NS309 binding pocket may include some additional amino acids from CaMBD 
and/or CaM, which do not contribute to formation of the PHU pocket or the 1-EBIO pocket 
used for molecular docking and MD simulations. Second, interactions of NS309 with its 
binding pocket may stabilize the CaM-CaMBD complex, as demonstrated by a recent 
study9. Such stabilizing effects are not reflected in our estimation of the binding energy (ΔG, 
Fig. 4e), which describes only the direct interaction between NS309 and the protein 
complex. Finally, it is also likely that different NS309 tautomers may have different effects 
on potentiation of the SK/IK channel activities, although this is a less likely scenario, since 
molecular docking shows that all three tautomers have the same conformation 
(Supplementary Fig. S3). Collectively, our results demonstrate that understanding of how 
compounds, such as 1-EBIO and NS309, interact with the binding pocket will shed light on 
how to improve the potency of the compounds of the 1-EBIO class.
Selectivity is another issue which hinders the development of more effective therapeutics 
targeting SK/IK channels11,28–32. With the exception of CyPPA, compounds of the 1-EBIO 
class as well as toxins, such as apamin, generally lack selectivity amongst SK1, SK2, SK3 
and IK channels36. Lack of the knowledge of how compounds of the 1-EBIO class interact 
with their binding sites is likely to be a major roadblock to successful development of more 
selective therapeutics. The A477V/L480M mutation not only enhances the potency of 1-
EBIO by 10-fold (Fig. 5), but also becomes almost insensitive to potentiation by CyPPA 
(Fig. 7), mimicking the profile of CyPPA on IK channels36. However, the results of the 
A477V/L480M mutation do not explain why SK1 channels fail to respond to CyPPA. 
Nevertheless, our results show the binding pocket, identified by our protein crystal 
structures, is at least partially responsible for the selectivity of CyPPA.
Protein-protein interactions and formation of macromolecular protein complexes are primary 
means of efficiency and specificity in cellular signaling42. Development of small molecular 
weight therapeutics targeting the interface of protein-protein interactions represents a new 
direction of drug discovery, with the biggest advantage of achieving selective actions on 
targets which are otherwise too common or widely distributed in cellular signaling43–46. 
Typically, the protein-protein interface is fairly large (~700–4000 Å2), and the size 
differences make it impossible for small molecules to completely block the protein-protein 
interactions like the traditional agonists/antagonists. Within the protein-protein interface, 
smaller regions, or “hotspots”, are responsible for a disproportionate contribution to the 
binding energy of the two interacting proteins and are targets for theraputics44–45. Our 
structure data show that the binding pocket for PHU and 1-EBIO includes L480 (Figs. 1 and 
3), which is the anchor residue interacting with the CaM hydrophobic pocket8,10, an 
important hotspot for the CaM-CaMBD interaction47–48. Thus, compounds of the 1-EBIO 
class represent another example targeting the protein-protein interface with biological 
consequences. Understanding the nature of how 1-EBIO and its related compounds interact 
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with the binding pocket will help develop compounds with better potency and selectivity 
targeting not only SK/IK channels but also other CaM-target protein complexes involved in 
Ca2+ dependent signaling47,49–51.
METHODS
Protein Expression and Purification
Briefly, rat CaM cDNA was cloned into pET-28b (Novagen), expressed in E. coli strain 
Rosetta2(DE3) (Novagen). CaM was purified using a low substitution phenyl sepharose fast 
flow column and an AKTA purifier (GE Healthcare). The codons of the CaMBD2-a were 
optimized for expression in E. coli and the synthetic gene was cloned into pET-28b. The 
sequence of CaMBD2-a used for expression is: 
MGRKLELTKAEKHVHNFMMDTQLTKRVKNAAANVLRETWLIYKNTKLVKKIDHA
KVRKHQRKFLQAIHQLR SVKMEQRKLNDQANTLVDLAKTQLEHHHHHH. The His-
tagged CaMBD2-a was expressed, solubilized with 0.2% w/v sarkosyl and purified on a 
nickel column (Qiagen). Both CaM and CaMBD2-a were subsequently purified a using 
Sephacryl S-100 high resolution gel filtration column (GE Healthcare). The protein 
concentrations were determined using predicted extinction coefficients. The CaM-CaMBD2-
a protein complex was formed by slowly adding the CaMBD2-a to CaM (at a final ratio of 
1:1). The complex was then purified using the gel filtration column (GE Healthcare) pre-
equilibrated in a solution with 10 mM Tris-HCl, 150 mM NaCl, and 10 mM CaCl2 (pH 7.5). 
Fractions were collected and the purified proteins were concentrated to 1 mM and stored at 
−80°C.
Crystallization and structure determination
Protein crystals of the CaM-CaMBD2-a complex were grown in hanging drops by vapor 
diffusion at 20 °C 8,10. The complex (1mM) was mixed in a 1:1 ratio with the reservoir 
solution, which consists of 1.25 M Li2SO4, 0.5 M (NH4)2SO4, 0.1 M sodium citrate, pH 5.6. 
Monoclinic crystals grew within 3 weeks. These preformed protein crystals were then 
incubated with SK channel modulators at their saturating concentrations for two days. The 
channel modulator-soaked protein crystals were flash-cooled in liquid nitrogen for data 
collection, after a brief transfer to a suitable cryoprotectant (reservoir solution saturated with 
SK channel modulators, supplemented by 25% glycerol). X-ray diffraction data were 
collected from single protein crystals at Beamline of the National Synchrotron Light Source 
(Brookhaven National Laboratory, Upton, NY) and at the SYBILS Beamline 12.3.1 at the 
Advanced Light Source (Berkeley, CA) and were processed using Xia252. The CaM-
CAMBD2-a complex structure determined in the absence of SK channel agonists (1G4Y) 8 
was used as a starting model to phase diffraction data. Solvent molecules were removed 
from the starting molecule prior to rigid body refinement against the channel modulator-
soaked diffraction data. The crystallographic model was further constructed through iterative 
rounds of manual model building using Coot53 and crystallographic refinement using 
REFMAC554 and PHENIX55. The SK channel modulators were modeled in a hydrophobic 
pocket of the N-lobe of CaM based on strong electron density in difference Fourier maps 
and successful refinement of the coordinates. The current refined models contain CaM 
residues 2 to 147 with two Ca2+ ions, and SK channel residues 395 to 404 and 413 to 489. 
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Crystallographic statistics for data collection and model refinement are summarized in Table 
1 for both models. Structure graphics were created using PyMol (Schrödinger, LLC).
Molecular docking
CHARMM-based molecular docking is performed for an all-atom force field potential 
energy description of the protein-ligand complexes56–58. The Generalized-Born with 
molecular volume (GBMV) implicit solvent model was used in the calculation of linear 
interaction energy “LIE(GBMV)” scores to ensure physically rigorous evaluation of 
electrostatic potential energy components for the evaluation of top-ranked ligand poses as 
described previously38–39. A two-step scoring approach for CHARMM-based molecular 
docking was used, where the LIE(GBMV) scoring function was used for the identification 
of the top-ranked ligand pose geometry, and then a regression-based pair potential (S2) was 
used to predict binding affinities for ranking compounds59. Both rigid-receptor and 
“flexible-receptor” approaches were used to characterize putative binding modes for five 
ligands, PHU, 1-EBIO, DCEBIO, NS309 and CyPPA. Flexible receptor docking models 
were initially developed from the structure of PHU-bound CaM-CaMBD, and later 
compared to the 1-EBIO-bound structure. Short 100-ps molecular dynamics (MD) 
simulations were performed from the structure of PHU-bound CaM-CaMBD using the 
GBMV implicit solvent model38. Similar MD simulations were also performed from some 
top-ranked predicted binding modes of 1-EBIO, DCEBIO and NS309, to generate an 
ensemble of flexible receptor models. For the ensemble of flexible receptors derived from 
the PHU-bound structure and from MD simulations, 15 total conformations were used, each 
of which is generated from the final minimized structure from short 100-ps MD simulations 
of top-ranked binding posed of DCEBIO (5 conformations) and NS309 (10 conformations). 
An ensemble of rigid-receptor models were also constructed from the PHU-bound crystal 
structure using the most energetically favorable rotamers of M71 and M72, and F68 
(backbone dependent DUNBRACK library)60. The rigid-receptor ensemble constructed 
from rotamers had 29 members, containing 9 rotamers of M71, 11 rotamers of M72, and 6 
rotamers of F68, and finally, three low energy conformations formed from low energy 
optimized combinations of M71 and M72. Receptor ensemble docking (RED) was then 
performed assuming that each individual conformation was a rigid-receptor40. RED was 
performed using the ensemble of flexible receptor conformations generated from MD (15 
conformations) and low-energy side chain rotamers built from the crystal structure (29 
conformations). Molecular docking was also used to characterize the effect of binding of the 
ligands to mutations modeled from the PHU-bound structure using all energetically 
favorable rotamers (backbone dependent DUNBRACK library)60. Mutations, such as 
A477M/L480M, A477L and A477I, were also modeled using the PHU-bound crystal 
structure as previously described60.
Electrophysiology
Details can be found in our previous papers10. Briefly, both SK2-a and SK2-b channels 
(WT) along with CaM, were subcloned into the pCDNA3.1 expression vector (Invitrogen) 
respectively. Mutations were introduced into SK2-a using the QuickChange XL site-directed 
mutagenesis kit (Stratagene-Agilent) and subsequently confirmed by DNA sequencing. All 
SK channel modulators were from Tocris, except CyPPA which was from Sigma-Aldrich. 
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WT and mutant channels, along with CaM and GFP, were expressed in TsA201 cells 
cultured in the Dulbecco’s modified Eagle’s medium (DMEM), with 10% fetal bovine 
serum and penicillin and streptomycin. A calcium phosphate method was used for 
transfection of SK2 cDNA (WT or mutants), together with CaM and GFP at a ratio of 
5:2.5:1 (weight). Channel activities were recorded 1 – 2 days after transfection, with a 
Multiclamp 700B or a Axon200B amplifier (Molecular Devices) at room temperature. 
pClamp 10.2 (Molecular Devices) was used for data acquisition and analysis. The resistance 
of the patch electrodes ranged from 3–7 MΩ. The pipette solution contained: 140 mM KCl, 
10 mM HEPES, 1 mM MgSO4, at pH 7.4. The bath solution contained: 140 mM KCl, and 
10 mM HEPES, at pH 7.2. EGTA (1 mM), HEDTA (1 mM) were mixed with Ca2+ to obtain 
0.2 μM free Ca2+ calculated using the software by Chris Patton of Stanford University 
(http://www.stanford.edu/~cpatton/maxc.html). The Ca2+ concentrations were verified using 
Fluo-4 and standard Ca2+ buffers (Molecular Probes). Currents were recorded using an 
inside-out patch configuration. For SK2-a and its mutants, the intracellular face was initially 
exposed to a zero-Ca2+ bath solution, and subsequently to bath solutions with 0.2 μM Ca2+. 
Currents were recorded by repetitive 1 sec-voltage ramps from −100 mV to +100 mV from a 
holding potential of 0mV. One minute after switch of bath solutions, ten sweeps, with a one-
second interval, were recorded at concentrations for the channel modulators in the presence 
of 0.2 μM Ca2+. For SK2-b channel, a 0.5 μM Ca2+ solution was used instead of 0.2 μM, 
because of its reduced Ca2+ sensitivity for channel activation10. The integrity of the patch 
was examined by switching the bath solution back to the zero-Ca2+ buffer. Data from 
patches, which did not show significant changes in the seal resistance after solution changes, 
were used for further analysis. To construct the dose dependent potentiation of channel 
activities, the current amplitudes at −90mV in response to various concentrations of a 
channel modulator were normalized to that obtained at maximal concentration. The 
normalized currents were plotted as a function of the concentrations of each channel 
modulator. EC50s and Hill coefficients were determined by fitting the data points to a 
standard dose-response curve (Y = 100/(1 + (X/EC50)^−Hill)).
Statistical analysis
All data are presented in mean ± s.e.m. The Student’s T-test is used for data comparison.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phenylurea binds to the CaM-CaMBD interface at the CaM N-lobe
(a) A space-filled model of the CaM-CaMBD2-b complex (3SJQ), depicting the location of 
PHU (yellow) between the interface of CaM (salmon) and CaMBD2-b (marine) at the CaM 
N-lobe. Only half of the 2×2 complex is shown for clarity. (b) Difference Fourier electron 
density map constructed using mFo–DFc coefficients calculated in PHENIX prior to 
modeling PHU and side chain rearrangements that occur in the binding site. The map is 
contoured at 2.5σ and displayed within a 6 Å sphere of PHU. The map is overlaid with the 
final coordinates for PHU and its surrounding amino acid residues in the CaM-CaMBD2-a 
complex. Marine are amino acid residues from CaMBD2-a and salmon are amino acid 
residues from CaM. Coordinates of the same amino acid residues (gray) from the original 
CaM-CaMBD2-a complex (without PHU, 1G4Y) are provided for comparison. (c) A space-
filled model of PHU at the CaM-CaMBD interface. Marine represents CaMBD and salmon 
represents CaM. (d) Comparison of the chemical structure of PHU with that of 1-EBIO and 
NS309. Both 1-EBIO and NS309 are known SK/IK channel modulators.
Zhang et al. Page 15
Nat Commun. Author manuscript; available in PMC 2013 February 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Phenylurea is a weak SK2 channel modulator
(a) Raw current traces from an inside-out patch with SK2-a channels expressed. The SK2 
channels are activated by 200 nM Ca2+, with subsequent potentiation by PHU at the 
concentrations indicated (all in the presence of 200 nM Ca2+). A voltage ramp, from −100 
mV to +100 mV, was applied. (b) Dose-response curves for PHU (n = 4) and 1-EBIO (n = 
5) for their potentiation of the SK2 channel activities (all in the presence of 200 nM Ca2+). 
The current amplitudes were measured at −90 mV and normalized to the maximal current 
obtained either with PHU or 1-EBIO. (c) EC50s of potentiation of the SK2 channel activities 
by PHU (n = 4), 1-EBIO (n = 5), DCEBIO (n = 8), CyPPA (n = 6) and NS309 (n = 3). All 
modulators were in a 200 nM Ca2+ solution. Note that the y-axis is in the log scale. (d) SK2-
a (n = 3) and SK2-b (n = 6) have the same responses to application of NS309. Because SK2-
b is less sensitive to Ca2+ for its activation, 500 nM Ca2+ was used instead of 200 nM Ca2+ 
for SK2-a channels. All data are mean ± s.e.m.
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Figure 3. The CaM-CaMBD interface harbors the binding pocket for 1-EBIO
(a) Difference Fourier electron density map constructed using mFo–DFc coefficients 
calculated in PHENIX prior to modeling 1-EBIO and side chain rearrangements that occur 
in the binding site. The map is contoured at 2.2s and displayed within a 6 Å sphere of 1-
EBIO. The map is overlaid with the final coordinates for 1-EBIO and its surrounding amino 
acid residues in the CaM-CaMBD2-a complex. Marine are amino acid residues from 
CaMBD2-a and salmon are amino acid residues from CaM. Coordinates of the same amino 
acid residues (gray) from the original CaM-CaMBD2-a complex (without 1-EBIO, 1G4Y) 
are provided for comparison. (b) Comparison of key amino acid residues which form the 
binding pocket for PHU (orange for CaMBD residues and purple for CaM residues) and that 
for 1-EBIO (marine for CaMBD residues and salmon for CaM residues). (c) Formation of 
the 1-EBIO binding pocket at the CaM-CaMBD interface. 1-EBIO disrupts the interaction 
between M71 of CaM (salmon) and A477/L480 of CaMBD (marine). (d) Overlay of the 
coordinates for 1-EBIO (yellow) and PHU (Cyan) obtained from their respective protein 
crystal structures.
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Figure 4. Other compounds dock into the same pocket as PHU and 1-EBIO
(a) Conformations of PHU and 1-EBIO determined from the crystal structures. They serve 
as reference conformations. (b) The predicted conformation of DCEBIO in the binding 
pocket (left), which is superimposed with the conformations of PHU or 1-EBIO (right). (c) 
The predicted conformation of NS309 in the binding pocket (left), which is superimposed 
with the conformations of PHU or 1-EBIO (right). (d) The predicted conformation of 
CyPPA in the binding pocket (left), which is superimposed with the conformations of PHU 
or 1-EBIO (right). (e) Correlation of the predicted binding free energies of the five ligands 
using the S2 scoring function and the EC50s of these compounds in potentiation of SK2 
channels. The EC50 for NS309 deviates from the prediction.
Zhang et al. Page 18
Nat Commun. Author manuscript; available in PMC 2013 February 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. A477V/L480M mutation increases the potency of 1-EBIO
(a) Sequence alignment of the fragments (equivalent of E469 to Q487 of SK2-a) of CaMBD 
at the CaM N-lobe from SK1, SK2, SK3 and IK channels. A477, L480 and V481 are 
implicated in formation of the binding pocket for the channel modulators from the structure 
data. Used in the alignment are the human SK1, SK3 and IK channel sequences and the rat 
SK2 channel sequence. (b) A space-filled model of the A477V/L480M mutation (green) 
with 1-EBIO in the binding pocket. Changes are made based on the structure data using 
Pymol. Note that T479 points away from 1-EBIO. (c) Dose-response curves for potentiation 
by 1-EBIO of the SK2 channel activities from WT (n = 5), T479S (n = 4) and A477V/
L480M (n = 4). 200 nM Ca2+ was present in all 1-EBIO solutions. (d) A477V/L480M 
mutation significantly increases the potency of 1-EBIO (10-fold). All data are mean ± s.e.m.
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Figure 6. Effects of replacing A477 with bulky amino acid residues
(a) A space-filled model of the A477L mutation (green) with 1-EBIO in the binding pocket. 
The Ala residue at position 477 is changed to Leu based on the structure data using Pymol. 
Introduction of such a bulky amino acid residue may interfere with the interaction of 1-
EBIO and its binding pocket. (b) A space-filled model of the A477I mutation (green) with 
NS309 in the binding pocket. NS309 is docked to the binding pocket using MD modeling 
from the structure of the 1-EBIO-bound CaM-CaMBD2-a complex. The A477I change is 
then made using Pymol. (c) Responses of the A477I mutant, from an inside-out patch, to 
sequential applications of solutions containing (1) 0 Ca2+, (2) 200 nM Ca2+, (3) 3 μM 
NS309 with 200 nM Ca2+, and (4) 0 Ca2+ (as indicated). The current amplitudes were 
measured at −90 mV. (d) Dose-response curves for potentiation by NS309 of the SK2 
channel activities from WT (n = 3), A477V/L480M (n = 4) and A477I (n = 3). 200 nM Ca2+ 
was present in all NS309 solutions. On average, the A477V/L480M mutation shifts the 
NS309 dose-response curve to the left by 3.4-fold, while the A477I mutation results in a 5-
fold shift of the NS309 dose-response curve to the right. All data are mean ± s.e.m.
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Figure 7. Responses of the A477V/L480M mutation to application of CyPPA
(a) A space-filled model of CyPPA docked into the binding pocket. Molecular docking and 
MD simulation were performed to dock CyPPA into the PHU binding pocket based on the 
structure of PHU in the CaM-CaMBD2-a complex. (b) A space-filled model of CyPPA 
docked into the binding pocket with the A477V/L480M mutation (green). Molecular 
docking and MD simulations were performed to introduce the A477V/L480M mutation and 
then docking of CyPPA. Note that the A477V/L480M mutation is predicted to force CyPPA 
to adopt a different conformation in the pocket. (c) The A477V/L480M mutation on the 
effect of CyPPA. Responses of the A477V/L480M mutant, from an inside-out patch, to 
sequential application of solutions containing (1) 0 Ca2+, (2) 200 nM Ca2+, (3) 100 μM 
CyPPA with 200 nM Ca2+, (4) 10 μM NS309 with 200 nM Ca2+ and (5) 0 Ca2+. The current 
amplitudes were measured at −90 mV. Note that CyPPA, at 100 μM, barely potentiates the 
mutant channel activity. (d) Responses of SK2 channels, WT (n = 6), V418T (n = 3) and 
A477V/L480M (n = 5), to increasing concentrations of CyPPA. 200 nM Ca2+ was present in 
all CyPPA solutions. Note that there is little response from the A477V/L480M mutant at the 
CyPPA concentration range tested. All data are mean ± s.e.m.
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Table 1
Crystallographic statistics
Data Collectiona
CaM-CaMBD2-a Complex with 
phenylurea
CaM-CaMBD2-a Complex with 1-EBIO
Space Group
Unit Cell Dimensions
C2
a=76.5 Å, b=66.9 Å, c=65.1 Å α=90.0°, 
β=93.3°, γ=90.0°
C2
a=77.0 Å, b=66.7 Å, c=64.9 Å α=90.0° β 
=94.0°, γ=90.0°
Wavelength (Å) 1.12 1.12
Resolution range (Å) 50–1.65 (1.69–1.65) 25–1.63 (1.67–1.63)
Completeness (%) 99.5 (99.7) 99.2 (99.5)
Total Observations 197,980 (14,626) 200,171 (15,060)
Unique Observations 39,245 (2,902) 40,567 (2,989)
Mean Redundancy 5.0 (5.0) 4.9 (5.0)
Mean I/σ(I) 22.5 (2.3) 12.3 (2.2)
Rmergeb 0.035 (0.645) 0.063 (0.595)
Rpimc 0.017 (0.319) 0.031 (0.288)
Model Refinementa
Resolution Range (Å) 50–1.65 (1.69–1.65) 50–1.63 (1.67–1.63)
Number of reflections 39,243 (2,804) 40,565 (2,886)
Rworkd 0.191 (0.294) 0.192 (0.265)
Rfreed 0.228 (0.341) 0.227 (0.304)
Number of atoms/Average B-factor (Å2) 2,310/37.9 2,354/34.6
 protein 2,069/37.2 2,069/33.5
 calcium ions 2/38.8 2/36.1
 solvent waters 208/42.0 250/41.1
 SK channel modulator 10/36.4 12/45.0
Phi/Psi angles most favored(%)/outliers(#) 98.7/0 98.3/0
r.m.s.d. bond angles (°) 1.264 1.258
r.m.s.d. bond lengths (Å) 0.011 0.011
aValues in parentheses refer to data in the highest resolution shell.
b
Rmerge = ΣhklΣj | Ij − 〈I〉 | /ΣhklΣj Ij. 〈I〉 is the mean intensity of j observations of reflection hkl and its symmetry equivalents.
c
Rpim (precision-indicating merge) = Σhkl (1/nhkl − 1)1/2 Σj | Ij − 〈I〉 | /ΣhklΣj Ij. n is the number of observations of reflection hkl.
d
Rcryst = Σhkl | Fobs − kFcalc | /Σhkl | Fobs |. Rfree = Rcryst for 5% of reflections excluded from crystallographic refinement.
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